Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vigil + Atezolizumab in Advanced Gynecological Cancers
NCT03073525Phase 2Completed
- Sponsor
- Gradalis, Inc.
- Start
- May 2017
- Primary completion
- May 2019
- Modality
- Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA), Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of gemogenovatucel-T in ovarian cancer, Cervical Cancer (CC), uterine cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by Gradalis, Inc.. Started May 2017; status: completed.
02
Drugs
gemogenovatucel-T
03
Conditions
ovarian cancerCervical Cancer (CC)uterine cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT03073525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03073525.